Biotech IV Monitor

SUPN — Supernus Pharmaceuticals Inc.

$2.7B market cap · 5 upcoming readouts tracked

Clinical trial readout dates for Supernus Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts5none in Phase 3
Market cap$2.7B
Cash & investments$305Mas of Sep 30, 2026
Recent 8-K filings3latest 2026-11-02

Upcoming readouts

Phase 1/2 BIS-001ER
Focal Impaired Awareness Seizures · NCT03474770
December 2026
Ongoing
Phase 2 SPN-821 2400 mg
Major Depressive Disorder (MDD) · NCT07226661
December 2026
Recruiting
Phase 2 SPN-817
Focal Onset Seizures · NCT06798896
August 2027
Recruiting
Phase 2 SPN-817
Epilepsy; Seizures, Epileptic · NCT05518578
December 2027
Recruiting
Phase 2 SPN-817
Focal Onset Seizures · NCT07141329
December 2027
Enrolling

Cash position

Supernus Pharmaceuticals Inc. reported $305M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). It reported net income of $137M for that quarter.

Recent SEC filings

8-K Reg FD Disclosure — often a data announcement2026-11-02
8-K Results of Operations — earnings, may carry pipeline updates2026-10-29
8-K Other Events — often topline trial data2026-10-22

Companies working on similar indications

Discussion

No messages yet. If you follow SUPN, you can start the conversation.
Track SUPN in real time
See live implied volatility for SUPN and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on SUPN
Contact — questions or corrections about SUPN: dukeupt@gmail.com